Margaret Chang, MD
Retina Specialist · Sacramento, CANPI 1477504405
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $136,717 of the $197,276 with a category attached, or 69.3%. 27 manufacturers reported payments, led by Genentech, Inc. at 24.3% of the total. 2025 is the largest year on record at $82,401, 7.1 times the $11,617 reported in 2019. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $785.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$48K
- Genentech USA, Inc.$43K
- F. Hoffmann-la Roche AG$28K
- Ocular Therapeutix, Inc.$26K
- Boehringer Ingelheim International GmbH$19K
- Roche Products Limited$18K
- plus $15K from 21 others
Across 1,081 payments — averaging $12,092 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$7.1M
- Genentech, Inc.$3.2M
- Ocular Therapeutix, Inc.$1M
- Modernatx, Inc.$458K
- Boehringer Ingelheim$358K
- Boehringer Ingelheim International GmbH$292K
- plus $651K from 6 others
What the payments were for
- Consulting fees$136,71769%
- Speaking & faculty fees$23,57612%
- Travel & lodging$28,54614%
- Food & beverage$8,3974%
- Gifts$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 21 | $47,862 |
| Genentech USA, Inc. | 66 | $43,394 |
| F. Hoffmann-la Roche AG | 10 | $28,003 |
| Ocular Therapeutix, Inc. | 22 | $26,011 |
| Boehringer Ingelheim International GmbH | 13 | $18,887 |
| Roche Products Limited | 5 | $17,709 |
| AbbVie | 5 | $2,586 |
| Astellas Pharma Global Development | 2 | $2,412 |
| Apellis Pharmaceuticals, Inc. | 29 | $2,067 |
| Eyepoint US, Inc. | 5 | $2,055 |
| Carl Zeiss Meditec, Inc. | 2 | $2,025 |
| Astellas Pharma US Inc | 23 | $2,014 |
| Regeneron Healthcare Solutions, Inc. | 9 | $492 |
| Regeneron | 7 | $370 |
| Amgen | 4 | $215 |
| Biogen | 6 | $186 |
| Coherus Oncology, Inc. | 3 | $165 |
| Harrow Eye, LLC | 3 | $161 |
| Novartis | 2 | $123 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $121 |
| Aerie Pharmaceuticals, Inc. | 1 | $115 |
| Mallinckrodt Hospital Products Inc. | 3 | $82 |
| Topcon Healthcare, Inc. | 1 | $60 |
| Alimera Sciences, Inc. | 3 | $57 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Carl Zeiss Meditec AG | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUSVIMO$40,987
- Lucentis$29,652
- VABYSMO$12,972
- Izervay$3,502
- EYP-1901$2,055
- CIRRUS 6000 with AngioPlex$1,215
- CLARUS$1,215
- FORUM Glaucoma Workplace$1,215
- Humphrey Field Analyzer (HFA3)$1,215
- Retina Workplace$1,215
- Syfovre$1,189
- CIRRUS HD-OCT$810
- Humphrey HFA$810
- IOLMaster 700$810
- VERACITY SURGICAL$810
- VisuMax$810
- EYLEA HD$494
- EYLEA$261
- PAVBLU$144
- Cimerli$125
How this compares
$197,276 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 201 | $6,404 |
| Prednisolone Acetate | 122 | $5,886 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $1,198 |
| Ofloxacin | 95 | $1,136 |
| Brimonidine Tartrate | 20 | $696 |
| Latanoprost | 50 | $543 |
| Dorzolamide Hcl | 14 | $244 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Sacramento
- Carlos Medina MendezSacramento$548K
- Glenn YiuSacramento$146K
- Joel PearlmanSacramento$33K
- David TelanderSacramento$18K
- Maryam GhiassiSacramento$10K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.